NASDAQ · PNT
POINT Biopharma Global Inc.
$12.50+$0.02 (+0.16%)
POINT Biopharma Global Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.89% below the high.
Loading market information…
NASDAQ · CINC · USD
Stock price, earnings
Quote as of Feb 23, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CinCor Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CinCor Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$12.50+$0.02 (+0.16%)
POINT Biopharma Global Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.89% below the high.
$9.10+$0.01 (+0.06%)
CTI BioPharma Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$2.34-$0.05 (-2.09%)
EQRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.74% below the high.
$16.87+$0.02 (+0.12%)
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
$11.13+$0.03 (+0.27%)
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$44.15$0.00 (0.0%)
Albireo Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.39% below the high.
$10.25+$0.01 (+0.05%)
Gracell Biotechnologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.77% below the high.
